| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,022 | 0,034 | 17:37 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.08. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.08.2025 | 1.088 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 28.08.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.08.2025.ISIN NameAU000000DHG9 DOMAIN... ► Artikel lesen | |
| 15.08. | Stagezero Life Sciences Ltd (2): Stagezero Life lists on NEX, remains suspended | 3 | Stockwatch | ||
| 14.08. | StageZero Life Sciences Ltd.: StageZero Announces Listing on the NEX Exchange | 1 | TheNewswire | ||
| 14.08. | Stagezero Life Sciences Ltd (2): Stagezero Life Sciences downgraded to NEX | 1 | Stockwatch | ||
| STAGEZERO LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 25.07. | Stagezero Life Sciences Ltd (2): Stagezero to delist from TSX, applies for NEX listing | 2 | Stockwatch | ||
| 25.07. | StageZero Life Sciences Ltd.: StageZero Announces Delisting from the TSX and a Concomitant Application for Listing on the NEX Exchange | 1 | TheNewswire |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CARL ZEISS MEDITEC | 40,300 | +0,15 % | Carl Zeiss Meditec: Hier wird es langsam interessant | Carl Zeiss Meditec liefert die Bilanz 2024/2025 ab ... und die Aktie bricht nach anfänglichen Gewinnen ein, markiert ein neues Jahrestief und ist seither nicht mehr in Gang zu bringen. Ein bärisches... ► Artikel lesen | |
| INTUITIVE SURGICAL | 489,40 | -0,88 % | Is ISRG's 20% Procedure Growth the New Normal or a Peak? | ||
| BOSTON SCIENTIFIC | 81,60 | +0,74 % | A Strong Growth Profile Gives Boston Scientific Corp. (BSX) a Favorable Outlook | ||
| PLUS THERAPEUTICS | 0,580 | +2,08 % | Plus Therapeutics Inc.: Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ in Leptomeningeal Metastases | HOUSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals... ► Artikel lesen | |
| MOUNTAIN VALLEY MD | 0,004 | -70,27 % | Mountain Valley MD Holdings Inc: Mountain Valley appoints Batchelor as director | ||
| ASENSUS SURGICAL | - | - | GlobalLogic, Asensus ink surgical robotics engineering collab | ||
| LIFEWARD | 0,648 | +2,68 % | Lifeward Ltd. Reports Third Quarter 2025 Financial Results | Record quarter of ReWalk systems placed for Medicare beneficiaries since fee schedule established Ongoing efficiency initiatives drive 16% year-over-year decrease in quarterly cash burn and 27%... ► Artikel lesen | |
| SENSEONICS | 5,100 | +0,99 % | XFRA 6L60: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| EKSO BIONICS | 5,560 | +1,65 % | Ekso Bionics Holdings, Inc.: Ekso Bionics Reports Third Quarter 2025 Financial Results | SAN RAFAEL, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial... ► Artikel lesen | |
| IMUNON | 2,960 | -1,33 % | Imunon, Inc.: IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update | R&D Day showcased remarkable Investigator optimism, continued strengthening supportive data, and significant progress with Phase 3 OVATION 3 Study in pursuit of first frontline immunotherapy for advanced... ► Artikel lesen | |
| BIOCEPT | 7,200 | 0,00 % | GlaxoSmithKline Bioc: Gewinn im zweiten Quartal bei 5,9 Mio. EGP | ||
| ROCKWELL MEDICAL | 0,709 | +1,36 % | Rockwell Medical appoints Joe Dawson to board of directors | ||
| MEMPHASYS | 0,002 | 0,00 % | MEMPHASYS LIMITED: Trading Halt | ||
| VIRIDIAN THERAPEUTICS | 27,150 | +1,08 % | Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit | ||
| SINTX TECHNOLOGIES | 3,740 | +5,65 % | SiNtx Technologies, Inc.: SINTX Technologies unterzeichnet Liefervertrag mit EVONIK zur Herstellung eines Siliziumnitrid-PEEK-Verbundwerkstoffes für KI-gestützte, 3D-gedruckte patientenspezifische Implantate | Ein Meilenstein, der die sofortige Produktion von maßgefertigten SiN/PEEK-Implantaten ermöglichtSALT LAKE CITY, Utah, Dec. 01, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) ("SINTX"... ► Artikel lesen |